GICS:pharmaceutical industry; market cap>100 billions

The pharmaceutical stocks that meet the criteria of having a market capitalization greater than $100 billion are as follows: |code|stock code|stock name|last-price|last-change|GICS Industry|Market Cap[20240701]|market_code| |---|---|---|---|---|---|---|---| |LLY|LLY.N|Eli Lilly|914.3700|0.9930|Pharmaceuticals|8.6902217279682E11|169| |NVO|NVO.N|Novo Nordisk|145.4200|1.8775|Pharmaceuticals|6.4766434623132E11|169| |JNJ|JNJ.N|Johnson & Johnson|146.4400|0.1916|Pharmaceuticals|3.5243409955852E11|169| |MRK|MRK.N|Merck|127.9000|3.3118|Pharmaceuticals|3.239459266653E11|169| |ABBV|ABBV.N|Abbvie|170.3700|-0.6705|Pharmaceuticals|3.0085089384897E11|169| |AZN|AZN.O|Astrazeneca|77.9400|-0.0641|Pharmaceuticals|2.4165395235576E11|185| |NVS|NVS.N|Novartis|106.5400|0.0751|Pharmaceuticals|2.1738489647098E11|169| |PFE|PFE.N|Pfizer|28.2200|0.8578|Pharmaceuticals|1.5991125158156E11|169| |SNY|SNY.O|Sanofi|49.5900|2.2053|Pharmaceuticals|1.2544286092542E11|185| These companies are some of the largest and most established in the pharmaceutical industry, which could be reflected in their market capitalizations. They are likely to have diversified product portfolios and strong financial positions. Investors looking for stability and potential long-term growth in the pharmaceutical sector may consider these stocks. However, it's important to conduct thorough due diligence, as these stocks may also be more sensitive to changes in the industry and regulatory environment.